Outcomes of Patients with Advanced Urothelial Carcinoma after Anti-programmed Death-(ligand) 1 Therapy by Fibroblast Growth Factor Receptor Gene Alteration Status: An Observational Study.
Anti–programmed death-(ligand) 1 therapy
FGFR alteration
Fibroblast growth factor receptor
Programmed cell death protein 1
Programmed death-(ligand) 1
Urothelial carcinoma
Journal
European urology open science
ISSN: 2666-1683
Titre abrégé: Eur Urol Open Sci
Pays: Netherlands
ID NLM: 101771568
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
accepted:
02
11
2022
entrez:
5
1
2023
pubmed:
6
1
2023
medline:
6
1
2023
Statut:
epublish
Résumé
Clinical outcomes of anti-programmed death‑(ligand) 1 (anti-PD-[L]1) therapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations ( To analyze the outcomes of patients with mUC and any In this noninterventional, retrospective, multicenter study, clinical practice data were collected from Investigator‑determined overall response rate (ORR), disease control rate (DCR), and overall survival (OS) were assessed in multivariate and unadjusted analyses. Ninety-four patients (66% men; median age, 63 yr) with mUC and known Some evidence of lower response rates and shortened OS following anti-PD-(L)1 therapy was observed in Patients with metastatic urothelial carcinoma and prespecified fibroblast growth factor receptor alterations (
Sections du résumé
Background
UNASSIGNED
Clinical outcomes of anti-programmed death‑(ligand) 1 (anti-PD-[L]1) therapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (
Objective
UNASSIGNED
To analyze the outcomes of patients with mUC and any
Design setting and participants
UNASSIGNED
In this noninterventional, retrospective, multicenter study, clinical practice data were collected from
Outcome measurements and statistical analysis
UNASSIGNED
Investigator‑determined overall response rate (ORR), disease control rate (DCR), and overall survival (OS) were assessed in multivariate and unadjusted analyses.
Results and limitations
UNASSIGNED
Ninety-four patients (66% men; median age, 63 yr) with mUC and known
Conclusions
UNASSIGNED
Some evidence of lower response rates and shortened OS following anti-PD-(L)1 therapy was observed in
Patient summary
UNASSIGNED
Patients with metastatic urothelial carcinoma and prespecified fibroblast growth factor receptor alterations (
Identifiants
pubmed: 36601039
doi: 10.1016/j.euros.2022.11.001
pii: S2666-1683(22)02681-7
pmc: PMC9806713
doi:
Types de publication
Journal Article
Langues
eng
Pagination
48-57Informations de copyright
© 2022 The Authors.
Références
Nat Med. 2021 Dec;27(12):2200-2211
pubmed: 34893775
Lancet Oncol. 2017 Mar;18(3):312-322
pubmed: 28131785
N Engl J Med. 2019 Jul 25;381(4):338-348
pubmed: 31340094
Eur Urol. 2019 Nov;76(5):599-603
pubmed: 31272788
Lancet Oncol. 2016 Nov;17(11):1590-1598
pubmed: 27733243
Eur Urol Oncol. 2021 Dec;4(6):1001-1005
pubmed: 32417369
J Clin Oncol. 2020 Aug 10;38(23):2658-2666
pubmed: 32552471
Lancet Oncol. 2021 Jul;22(7):931-945
pubmed: 34051178
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
Cancer Immunol Res. 2016 Jul;4(7):563-8
pubmed: 27197067
Lancet Oncol. 2020 Dec;21(12):1574-1588
pubmed: 32971005
Eur Urol Focus. 2021 Nov;7(6):1339-1346
pubmed: 32861617
Br J Cancer. 2021 Oct;125(9):1251-1260
pubmed: 34294892
Lancet. 2018 Feb 24;391(10122):748-757
pubmed: 29268948
Cell. 2017 Oct 19;171(3):540-556.e25
pubmed: 28988769
Sci Rep. 2020 Jan 29;10(1):1439
pubmed: 31996725
Lancet Oncol. 2019 Oct;20(10):1454-1466
pubmed: 31405822
Eur Urol. 2021 Jul;80(1):7-11
pubmed: 33902955
Nat Rev Cancer. 2015 Jan;15(1):25-41
pubmed: 25533674
Transl Oncol. 2020 Mar;13(3):100738
pubmed: 32114384
Ther Adv Urol. 2019 Apr 04;11:1756287219839285
pubmed: 31057668
J Clin Oncol. 2019 Oct 10;37(29):2592-2600
pubmed: 31356140